Shanghai Securities News China Securities Network News (Reporter Luo Min) Fujilai disclosed abnormal fluctuations in stock trading and announced thatp0werballresultsyesterday, the company is concerned that some media, stock bar and other platforms discussed the company's business involving synthetic biology and related hot concepts. Biological enzymatic catalysis is the development trend for preparing R-lipoic acid. The company's biological enzymatic catalysis method has achieved mass production and is mainly used for external sales and preparation of R-lipoic acid sodium salt. It is still in the market promotion stage. Whether the original process can be completely replaced depends on many factors such as market demand and customer acceptance. In 2023, the company's income from such businesses will not exceed 3% of the company's operating income, which is relatively small, and there is no clear plan to expand production yet.
您的位置>首页
>Beverage
p0werballresultsyesterday|富士莱:公司生物酶催化法生产的R-硫辛酸已实现量产 目前尚处于市场推广阶段
Shanghai Securities News China Securities Network News (Reporter Luo Min) Fujilai dis...
本文为editor原创文章,转载请保留版权和出处:http://www.ntlyxf.com/Beverage/1864.html
评论列表